Pharmaceutical

Insulin Pricing

Manufacturers and pharmacy benefit managers face price-fixing claims for inflating insulin costs by hundreds of percent over two decades.

Overview

Patients with Type 1 and Type 2 diabetes have paid dramatically inflated insulin prices for years. ELG is part of consolidated litigation pursuing manufacturers (Eli Lilly, Novo Nordisk, Sanofi) and pharmacy benefit managers (CVS Caremark, Express Scripts, OptumRx) for alleged price-fixing and kickback schemes.

Who is affected

  • Patients who paid out-of-pocket for analog insulin
  • Self-insured employers and health plans
  • Diabetic patients who rationed insulin due to cost

Conditions and diseases

  • Financial harm (out-of-pocket overpayment)
  • Diabetes complications from rationing (DKA, vision loss, amputation)
Free, Confidential Case Evaluation

Tell us what happened. We’ll tell you whether you have a case.

No fee unless we recover for you. All consultations are confidential and protected by attorney–client privilege.